Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71335-0165

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine Hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules, 20 mg. The diagram shows the molecular arrangement including fused aromatic rings and a thiophene group, with the hydrochloride indicated.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time in days from randomization. The chart compares two treatments: placebo (dashed line) and Duloxetine delayed-release capsules (solid line), illustrating that patients on Duloxetine have a lower relapse rate during the study period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time in days from randomization between placebo and Duloxetine delayed-release capsules. The x-axis represents time in days up to 300 days, and the y-axis represents the proportion of patients with relapse ranging from 0 to 1. The graph shows two lines: a dashed line for placebo and a solid line for Duloxetine delayed-release capsules.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares four groups: DUL 60mg BID, DUL 60mg QD, DUL 20mg QD, and Placebo, showing trends in pain improvement across these groups.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph displays that higher percentages of patients improved pain with Duloxetine compared to placebo across varying levels of pain improvement.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows patient improvement trends across different levels of pain reduction.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph showing the percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph compares Duloxetine (DUL) doses of 20 mg, 60 mg, and 120 mg once daily, along with a placebo group, illustrating their relative effects on patient pain improvement.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release capsules at doses of 60/120 mg once daily and placebo. The graph shows two curves illustrating patient response percentages across different pain improvement thresholds.*

FDA Label Image

Duloxetine 09

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60 mg once daily. The graph shows two curves indicating patient response rates over a range of pain improvement percentages, with Duloxetine generally showing higher percentages of patient improvement than placebo.*

FDA Label Image

Duloxetine 10

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for placebo and Duloxetine delayed-release 60/120 mg once daily. The graph shows two curves depicting patient improvement rates across various pain improvement thresholds.*

FDA Label Image

Label Image (Lbl713350165)

Label for Duloxetine HCL DR 20 mg Capsule, a delayed-release oral capsule. The label indicates comparison to Cymbalta 20 mg Capsule by Towa Pharmaceutical Europe, S.L. It includes packaging details by Bryant Ranch Prepack, storage instructions at 20°-25°C (68°-77°F), and advisory that it may cause drowsiness. The NDC 7133501651 and a barcode are visible, along with lot number 1523487.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.